Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition by Rossi, Rosario et al.
 ‘Early Atherosclerotic Clinic’ (Bene Essere Donna & Cardiometabolic 
Center) of the Policlinico Hospital, Institute of Cardiology, University of 
Modena and Reggio Emilia, Italy
Corresponding author:
Rosario Rossi, Institute of Cardiology, Policlinico Hospital,  
Via del Pozzo, 71–41100 Modena, Italy.  
Email: rossi.rosario@unimore.it
Journal of the Renin-Angiotensin-
Aldosterone System
12(4) 446 –455
© The Author(s) 2011
Reprints and permission:  
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1470320311415134
jra.sagepub.com
Article
Effects of antihypertensive treatment on 
endothelial function in postmenopausal 
hypertensive women. A significant role  
for aldosterone inhibition
Rosario Rossi, Annachiara Nuzzo, Daniele Iaccarino, Antonella Lattanzi,  
Giorgia Origliani, Daniel Enrique Monopoli and Maria Grazia Modena
Abstract 
Introduction: Endothelial dysfunction is a well-demonstrated independent predictor of cardiovascular events in hypertensive 
postmenopausal women. Accordingly, it is plausible that improving endothelial function could represent an adjunctive 
target for antihypertensive treatment. The aim of our study was to evaluate the effect of pharmacologic treatment on 
endothelial function in the specific population of hypertensive postmenopausal women.
Methods: A total of 320 consecutive hypertensive postmenopausal women underwent a high-resolution ultrasound study 
of the brachial artery at baseline and after six months, while ‘optimal’ control of blood pressure (maintenance of blood 
pressure values below 140/90 mmHg at all follow-up visits) was achieved using antihypertensive therapy. Endothelial 
function was measured as flow-mediated dilation, using ultrasound method.
Results: After six months of treatment, flow-mediated dilatation (FMD) had significantly improved in the majority of 
patients (n = 257  [80.3% of the entire population];  FMD = 8.1 ± 1.0% at baseline vs. 10.6 ± 1.5% after follow-up; p < 
0.001), but it had not changed or worsened in others (n = 63 [19.7%]; FMD = 8.2 ± 1.2% at baseline vs. 7.6 ± 1.0% after 
six months; p = ns). Improvement of endothelial function, at multivariate analysis, resulted independently associated with 
the use of aldosterone inhibitors (odds ratio = 2.15; 95% confidence interval: 1.55–2.75; p = 0.001).
Conclusions: This study demonstrates that a significant improvement in endothelial function may be obtained after six 
months of an optimal antihypertensive therapy. Among all hypertensive postmenopausal women that achieved an optimal 
control of blood pressure during follow-up, the use of drugs that inhibit aldosterone receptors was associated with an 
improvement of endothelial function, beyond the ‘optimal’ blood pressure control.
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Introduction
Endothelium plays an important role in the modulation of 
vascular tone. The major endothelium-produced relaxing 
factor is nitric oxide (NO), which is derived from L-arginine 
by the activity of the enzyme NO-synthase.1 Since 1992, 
the non-invasive measurement of brachial artery flow-
mediated dilation (FMD) has been used to evaluate endothe-
lial function, because FMD largely depends on the ability 
of the endothelium to produce NO.2
Essential hypertension is characterized by impaired 
endothelium-dependent vasodilation,3,4 and it has been sug-
gested that endothelial dysfunction could act as a promoter 
of hypertension in apparently healthy postmenopausal 
women.5 Moreover, endothelial dysfunction resulted an 
independent predictors of cardiovascular events in patients 
with hypertension.6-9 This fact was expressly demonstrated, 
by our group, in hypertensive postmenopausal women.10 
Accordingly, it is plausible that reversing endothelial dys-
function could represent an adjunctive target for antihyper-
tensive treatment. However, it has been widely established 
that simple blood pressure reduction is not sufficient 
to improve or restore endothelial dysfunction.10 This 
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beneficial effect can be achieved only by specific mecha-
nisms not shared by all drug classes.11-13 
In the present study we addressed the effect of six 
months’ antihypertensive treatment with different antihy-
pertensive drug classes, on flow-mediated, endothelium-
dependent, vasodilatation of the brachial artery, in a cohort 
of postmenopausal women with essential hypertension.
Subjects and methods
Patients
Postmenopausal patients with newly diagnosed hyperten-
sion, according to the European Guidelines for the manage-
ment of arterial hypertension,14 were eligible for the study.
Menopause was defined by the absence of menstruation 
for at least 12 months or by the dosage of hormone serum 
level (follicle-stimulating hormone > 40 IU/L and 17 beta-
estradiol < 110 pmol/L).
The patients’ history, physical examination, 12-lead 
electrocardiogram, and echocardiogram were used to 
exclude past or present heart disease. Three hundred and 
thirty-two consecutive women were enrolled. All gave their 
informed consent to participate in this prospective cross-
sectional study, which had been approved by the Science 
and Ethic Committee of our university.
Study protocol 
Enrolled postmenopausal women underwent a study of the 
endothelial function (ultrasound study of the brachial artery) 
at baseline. A second evaluation was scheduled for six 
months later. In the interim, patients were to receive antihy-
pertensive treatment. Therapies were assigned to maintain 
systolic BP < 140 mmHg and diastolic BP < 90 mmHg. 
Patients were visited every four weeks. The choice of anti-
hypertensive drug used was at the discretion of the study 
investigators, and was made on the basis of a step-by-step 
approach, when the BP values were unsatisfactory (≥ 140/≥ 
90 mmHg). Women were excluded from the study for the 
following reasons: hypertension due to identifiable cause; a 
failure to achieve a BP < 140/< 90 mmHg after six months 
of treatment; achieved the desired values of BP with only 
changes in lifestyle, therefore, no use of antihypertensive 
drugs; an improbability of remaining geographically acces-
sible for study visits; current participation in other ongoing 
clinical trials.
Evaluation of endothelial function
Endothelial function was assessed by the measurement of the 
flow-mediated (endothelial-dependent) dilatation performed 
on the brachial artery. FMD of the brachial artery was meas-
ured without knowledge of the patient’s clinical data. 
The technique for assessing brachial artery FMD has 
been described in detail elsewhere.2,10,15,16 Briefly, FMD 
was assessed in the subject’s right arm in the recumbent 
position after a 15-min equilibration period in a tempera-
ture-controlled room (22°C to 25°C) by a high resolution 
ultrasound instrument GE Vivid E, with a 5- to 12-MHz 
linear array multifrequency transducer (General Electric 
Company, Fairfield, CT, USA). The brachial artery was 
longitudinally imaged ~ 5 cm proximal to the antecubital 
crease, where the clearest image was obtained, and the 
diameter at end diastole was measured (the mean of three 
measurements was used in the analysis). A pressure cuff, 
placed on the forearm (distal to the target artery), was 
inflated until no blood flow was detected through the bra-
chial artery with the Doppler probe. After 5 min, the cuff 
was released, and this was followed by an increase in blood 
flow. This phenomenon increased shear stress, which 
served as the stimulus to induce dilatation. After cuff 
release, the diameter of the brachial artery was measured at 
45, 60, 90, 180, and 300 s. The maximum diameter in any 
of these measurements was used in the calculation of FMD 
according to the following formula: (maximum diameter 
during reactive hyperaemia - diameter at baseline)/diameter 
at baseline %.
The same procedure, performed after administration of 
0.4 mg of sublingual nitroglycerin, allowed us to calculate 
the nitroglycerin-mediated dilatation.
Intrareader reproducibility for baseline diameter, maxi-
mum diameter, and FMD was evaluated by comparing an 
original and a blinded quality control reread of ultrasounds 
from 50 consecutive women in our centre. The intraclass 
correlation coefficients were 0.99, 0.99, and 0.89, respec-
tively. Intrasubject variability was evaluated by comparing 
results from repeated examinations of 50 women on two 
days a week apart. The intraclass correlation coefficients 
for baseline diameter, maximum diameter, and FMD were 
0.94, 0.92, and 0.78, respectively. Per cent technical error 
of measurement was 0.45% for baseline diameter measure-
ment, 0.78% for maximum diameter measurement, and 
7.4% for FMD measurement.
Statistical analysis
Statistical analysis was performed using SPSS software 
version 15.0 (SPSS Inc., Chicago, IL, USA). Data were 
expressed as mean ± one SD for normally distributed con-
tinuous variables. Dichotomous parameters were summa-
rized as a percentage. The two studied groups were 
compared, at baseline, by the Student t test for unpaired 
data and the chi-square test with Yate’s correction for con-
tinuity, as appropriate. Correlation between continuous 
variables were tested using the Pearson r test.
To assess the independent correlates of improvement of 
endothelial function during follow-up, we constructed a 
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model of multivariate binary logistic regression analysis 
including FMD as a dependent variable (FMD improvement 
vs. FMD non-improvement during follow-up), as well as the 
other parameters related to the brachial artery ultrasound 
study (brachial artery diameter and nitroglycerin-mediated 
vasodilatation), a series of traditional risk factors (age, heart 
rate, smoking habit, body mass index, hypercholesterolemia, 
type II diabetes, and serum levels of fasting glucose, total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycer-
ides), liver and renal function derived parameters, serum 
electrolytes, one indicator of effectiveness of antihyperten-
sive therapy (systolic and diastolic BP decline during follow-
up), and the use of antihypertensive and non-antihypertensive 
drugs during follow-up, as a covariate. In addition, we evalu-
ated the power of the dual-blockade of the renin–angiotensin–
aldosterone system (RAAS) (concomitant use of an 
aldosterone inhibitor + ACE-inhibitor or angiotensin recep-
tor blocker) in the ability to influence FMD improvement.
All probability values are two-tailed, and statistical sig-
nificance was considered as rejection of the null hypothesis 
with > 95% confidence.
Results
The study included 320 consecutive postmenopausal 
women with essential hypertension. All of these patients, at 
baseline, underwent an ultrasound study of the brachial 
artery, with the first determination of FMD. At the second 
evaluation (six months after antihypertensive drug treat-
ment), FMD had significantly improved in the majority of 
patients (n = 257  [80.3% of the entire population]; group 1: 
improved FMD); but it had not changed or worsened in oth-
ers (n = 63 [19.7%]; group 2: not improved FMD). In 
patients of the latter group we observed that FMD values 
were unchanged (with respect to baseline) in 33 cases 
(10.3% of the entire population), whereas they were reduced 
in 30 patients (9.4% of the entire population).
Demographics, clinical, and brachial artery characteris-
tics of the two study groups are shown in Table 1. 
With regard to the assumed drugs, we noted 71 women 
(22.2% of the entire population) taking only one antihyper-
tensive medication; 176 (55.0%) two; 52 (16.3%) three; 
and 21 (6.5%) four or more. One hundred fifty-six of 320 
patients (48.7%) were taking (alone or associated) a thi-
azide diuretic; 121 (37.8%) an angiotensin-converting 
enzyme (ACE) inhibitor; 120 (37.5%) an angiotensin 
receptor blocker (ARB); 102 (31.9%) a calcium channel 
blocker; 83 (25.9%) a beta adrenergic blocker; 49 (15.3%) 
an aldosterone receptor blocker; 36 (11.2%) a loop diuretic; 
and 35 (10.9%) an ‘other’ antihypertensive drug. The anti-
hypertensive regimens and proportion of subjects who 
received ACE inhibitors, ARBs, calcium channel blockers, 
beta-blockers and diuretics, alone or combined, or other 
drugs, are shown in Table 2.
The results of multivariate regression analysis are shown 
in Table 3. Improvement of endothelial function, expressed 
as FMD, resulted independently associated with the use of 
aldosterone inhibitors. Such drugs affect endothelial func-
tion beyond BP decline. Among all used drugs, only this 
class of antihypertensive medication is able, in our experi-
ence, to independently influence endothelial function dur-
ing follow-up. The power of the single potential prognostic 
factor, evaluated using regression analysis, is shown in 
Table 4. There are other parameters that influence the out-
come of the study. i.e. systolic BP change during follow-up, 
and the two-level blockade of the RAAS. These parameters, 
although statistically significant, are not independently able 
to influence the improvement of FMD during follow-up.
The relationship between systolic BP decline and FMD 
improvement during follow-up is shown in Figure 1.
Regarding the 49 patients receiving aldosterone inhibi-
tors, only two patients were taking spironolactone, at a dose 
of 25 mg/day (these patients were those included in the group 
that did not improve their endothelial function during follow-
up); 25 patients assumed potassium canrenoate, at a dose of 
50 mg/day; and 22 canrenone, at a dose of 50 mg/day. All 
hypertensive women included in these last two subgroups 
significantly improved their endothelial function during fol-
low-up. In Italy eplerenone, a selective aldosterone receptor 
blocker, is not commercially available. All of the aldosterone 
inhibitors used in the present study are non-selective. 
In the present study aldosterone inhibitors were assumed 
in association with diuretics (loop or thiazide) in all 49 
treated patients. These drugs were included in the pharma-
cological scheme of treatment in the second step in 10/49 
patients (20.4%); in the third step in 31 (63.3%); and in the 
fourth step in eight patients (16.3%).
To better evaluate the characteristics of patients taking 
aldosterone receptor inhibitors, we further divided our pop-
ulation into two groups: patients taking versus patients not 
taking aldosterone receptor inhibitors. The results of this 
comparison are shown in Table 5. It is important to empha-
size a) that the dual blockade of the RAAS (concomitant use 
of an aldosterone inhibitor + ACE-inhibitor or ARB) was 
used in a significantly greater proportion of patients in the 
group treated with aldosterone inhibitors. No patient in our 
series has been treated using the association of ACE-
inhibitor + ARB or all the three RAAS-blocking agents. b) 
Patients taking aldosterone inhibitors do not show signifi-
cant elevation of serum potassium nor significant deteriora-
tion of renal function during follow-up, compared with 
other patients. These facts are probably due to the low dose 
of prescribed medications and, above all, because in our 
experience the aldosterone inhibitor is always used in asso-
ciation with (thiazide or loop) diuretics. c) The relatively 
low-dose of aldosterone inhibitors used accounts for the fact 
that none of our patients have experienced potentially drug-
related side effects, such as gynaecomastia or hirsutism.
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Discussion
One of the main results of the present study is that not all 
hypertensive postmenopausal women treated with antihy-
pertensive drugs improved their endothelial function, 
although their BP levels were effectively controlled. In 
other words, a proportion of hypertensive postmenopausal 
women (about one in five, in our study) that did not 
improve, or even worsened, their FMD despite achieving 
target BP. We do not know the true reason why this 
happens, but we know that these subjects have a worse 
prognosis, having a higher risk (compared with those who 
improve their endothelial function) of suffering cardio- and 
cerebro-vascular events.9,10,12
An important finding of our study is that treatment with 
ACE inhibitors and/or ARBs has not emerged as an inde-
pendent factor able to significantly influence FMD in hyper-
tensive postmenopausal women. These agents have been 
shown to improve endothelial function in several studies,17-20 
Table 1. Main demographic, anthropometric, clinical and brachial artery characteristics of the patients, divided according to the 
behaviour of endothelial-mediated vasodilation during follow-up
Parameter Group 1: 
improved FMD
(n = 257)
Group 2: 
non-improved FMD
(n = 63)
Demographic, anthropometric, clinical variables and cardiovascular risk factors, at baseline
Age, years 56 ± 7 57 ± 6
Current smokers 21.4% (n = 55) 23.8% (n = 15)
Total cholesterol, mg/dl 206 ± 46 207 ± 40
HDL cholesterol, mg/dl 48 ± 14 54 ± 16
LDL cholesterol, mg/dl 112 ± 40 110 ± 37
Hypercholesterolemia 32.7% (n = 84) 31.7% (n = 20)
Triglycerides, mg/dl 152 ± 90 156 ± 98
Glucose, mg/dl 102 ± 28 103 ± 26
Type 2 diabetes mellitus  8.2% (n = 21)  7.9% (n = 5)
BMI, kg/m2 27.5 ± 4.3 27.8 ± 4.6
Obesitya 
(BMI ≥ 30 kg/m2)
 7.0% (n = 18)  6.3% (n = 4)
Heart rate, bpm 80 ± 14 77 ± 11
Framingham Risk Scoreb 7.4 ± 6.3 7.3 ± 6.5
Liver function-related parameters, at baseline
Total bilirubin, mg/dl 0.72 ± 0.37 0.75 ± 0.39
AST, IU/L 23 ± 10 22 ± 7
ALT, IU/L 28 ± 18 28 ± 16
γ-GT, IU/L 37 ± 29 36 ± 28
Renal function-related parameters, at baseline
Creatinine, mg/dl 0.92 ± 0.26 0.91 ± 0.21
BUN, mg/dl 31 ± 10 31 ± 10
Uric acid, mg/dl 5.6 ± 1.3 5.4 ± 1.3
Serum electrolytes, at baseline
Sodium, mEq/L 138 ± 5 139 ± 4
Potassium, mEq/L 3.9 ± 0.4 4.1 ± 0.5
Medication, other than antihypertensive drugs, at baseline
Statins 31.1% (n = 80) 30.1% (n = 19)
Oral hypoglycaemic drugs  8.2% (n = 21)  7.9% (n = 5)
Brachial artery characteristics, at baseline
BAD, mm 3.8 ± 0.6 3.9 ± 0.5
FMD, % 8.1 ± 1.0 8.2 ± 1.2
NTG-MD, % 17.2 ± 2.0 16.9 ± 2.1
Brachial artery characteristics, after six months of follow-up
BAD, mm 3.9 ± 0.7 3.9 ± 0.6
FMD, % 10.6 ± 1.5c 7.6 ± 1.0d
NTG-MD, % 17.5 ± 2.2 17.4 ± 2.3
Data are presented as mean value ± one SD, or number (%) of patients. aAccording to the World Health Organization definition. bhttp://www.
mdcalc.com/framingham-cardiac-risk-score. cp < 0.001 intra-group (vs. baseline) comparison. dp = 0.02 intra-group (vs. baseline), and  
p < 0.0001 inter-groups (vs. group 1) comparisons. ALT: alanine aminotransferase, AST: aspartate aminotransferase, BAD: brachial artery diameter, 
BMI: body mass index, BUN: blood urea nitrogen, FMD: flow-mediated dilation, HDL: high-density lipoprotein, LDL: low-density lipoprotein,  
NTG-MD: nitroglycerin-mediated dilation, γ-GT: γ-glutamil transferase.
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but in our population, because they have been used in the vast 
majority of cases (about 75% of our patients received or an 
ACE inhibitor or an ARB), were not able, statistically, to sig-
nificantly influence FMD. These important drugs appear to 
be, rather, the ‘standard of care’ of antihypertensive drug 
treatment of postmenopausal women, in our experience.
The only class of drugs that clearly emerged as an inde-
pendent factor able to significantly improve endothelial 
function in hypertensive postmenopausal women is aldos-
terone receptor blockers. 
Aldosterone, aldosterone inhibition, and endothelial 
function 
Normalization of elevated BP in hypertensive individuals is 
associated with reduced target-organ damage and incident car-
diovascular morbidity and mortality. Endothelial dysfunction 
may precede hypertension,5 and many clinical manifestations 
of end-organ damage,21 and predict the occurrence of future 
cardiovascular events in hypertensive postmenopausal 
women.9,10,12 Activation of the renin–angiotensin–aldoster-
one system has been associated with increased cardiovascular 
morbidity and mortality. Antihypertensive drugs that inter-
fere with the RAAS exert, in fact, beneficial effects on vascu-
lar structure in hypertensive patients at variable risk for 
cardiovascular diseases.18,19,22
Aldosterone is a mineralocorticoid synthesized not only 
in the adrenal cortex but also in blood vessels.23 Aldosterone 
exerts significant pathophysiological effects on the cardio-
vascular system and causes vascular injury in the brain, 
heart, and kidneys.24
Several studies has reported that aldosterone contrib-
utes to endothelial dysfunction. Acute short-term systemic 
administration of aldosterone to young healthy subjects at 
a dose that increases aldosterone to plasma levels similar 
to those observed in patients with chronic heart failure 
Table 2. Blood pressure values at baseline and after six months of treatment, and the antihypertensive regimen: a comparison 
between groups
Parameter Group 1: 
improved FMD
(n = 257)
Group 2: 
non-improved FMD
(n = 63)
Baseline blood pressure (systolic/diastolic), mmHg 157 ± 15 / 94 ± 10 156 ± 14 / 93 ± 9
Blood pressure after 6 months
(systolic/diastolic), mmHg
134 ± 12 / 83 ± 9a 133 ± 13 / 84 ± 9a
Regimen
Single-drug therapy 22.3% (n = 58) 22.3% (n = 13)
Two antihypertensive drugs 55.2% (n = 142) 53.9% (n = 34)
Three antihypertensive drugs 15.9% (n = 41) 17.5% (n = 11)
Four or more antihypertensive drugs 6.6% (n = 17) 6.3% (n = 4)
Antihypertensive drugs usedb
ACE inhibitors 39.6% (n = 102) 36.5% (n = 23)
ARB 36.9% (n = 95) 39.6% (n = 25)
Calcium channel blockers 31.9% (n = 82) 31.7% (n = 20)
Beta adrenergic blockers 26.0% (n = 67) 25.4% (n = 16)
Thiazide diuretics 48.6% (125) 49.2% (n = 31)
Loop diuretics 11.3% (n = 29) 11.1% (n = 7)
Aldosterone receptor blockers 18.3% (n = 47) 3.2% (n = 2)c
Dual blockade of RAAS  
(aldosterone receptor blocker + ACE-inhibitor or ARB)
15.2% (n = 39) 3.2% (n = 2)c
Other antihypertensive drugs 10.5% (n = 27) 9.5% (n = 6)
Data are presented as mean value ± one SD or number (%) of patients. ap < 0.0001 vs. baseline. bAlone or combined. cp < 0.0001, inter-group 
comparison. ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blockers, RAAS: renin–angiotensin–aldosterone system.
Table 3. The independent parameters correlated with ‘improvement of the flow-mediated dilation’ during follow-up, as resulted in 
the multivariate regression analysis
Parameter B SE Wald p Exp(B) CI for Exp(B)
Use of aldosterone receptor blockers 1.87 0.73 6.4 0.001 2.15 1.55–2.75
Constant 2.21 0.79 7.7 0.0001 3.18 –
Use of aldosterone receptor blockers is expressed as categorical variables (use vs. non-use). CI: confidence interval, Exp(B): odds ratio, SE: standard 
error.
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reduced the response to acetylcholine, a well-known 
endothelial-dependent vasodilator.25 This detrimental 
effect was observed without changes in blood pressure 
levels, suggesting that aldosterone is able to impair 
endothelial function through non-haemodynamic mecha-
nisms. Treatment with the mineralocorticoid receptor 
antagonist ameliorated endothelial responses to acetylcho-
line in rats infused with angiotensin II, suggesting that 
aldosterone mediates vascular reactivity alterations 
induced by angiotensin II.26 In addition, aldosterone has 
been shown to be involved in the pathogenesis of hyper-
tension.27 Several mechanisms can underlie the deleteri-
ous effects of aldosterone on endothelium, with one 
important effect being decreased nitric oxide availability.28 
However, in patients with hypertension and/or left ven-
tricular hypertrophy/dysfunction, treatment with miner-
alocorticoid receptor antagonists have shown a beneficial 
effect in improving cardiac performance and cardiovascu-
lar mortality.29
Mineralocorticoid antagonism attenuates cardiovascular 
damage by mechanisms that seem to be in part independent 
of changes in BP values and that involve direct blockade of 
aldosterone’s cardiovascular pro-inflammatory and pro-
fibrotic effects.30 Aldosterone induces fibrosis in the heart, 
blood vessels, and kidney, particularly in the presence of high 
salt,31 and the antagonism of mineralocorticoid receptors has 
been associated with reduced fibrosis in human myocardium, 
limited ventricular remodelling and improved survival in 
patients with ventricular dysfunction and heart failure.30-34 
Our data suggest an additional mechanism by which aldos-
terone may exert its negative effect on the development of 
cardiovascular events, namely endothelial dysfunction.
Potassium canrenoate is a competitive non-selective 
inhibitor of aldosterone receptor; its pharmacologic activity 
is due to a rapid conversion to canrenone, which is the active 
metabolite. Potassium canrenoate is rapidly and completely 
absorbed from the gastrointestinal tract and bypasses the 
liver unchanged. Canrenone and canrenoate are in enzy-
matic equilibrium in vivo, in which canrenoate represents 
the derived γ-hydroxycarboxylic acid.35 The bioavailability 
and water solubility of potassium canrenoate are greater 
than those of spironolactone; therefore the number of active 
metabolites of the latter is considerably greater.35 These two 
drugs (potassium canrenoate and canrenone), used in hyper-
tensive postmenopausal women, significantly improve 
endothelial function, independently of the reduction of BP 
values.
Study limitations
Our study has some limitations in that it is an observational, 
non-randomized study. 
Table 4. Potential predictors of FMD progression evaluated using regression analysis
Parameter Score p
Age, years 1.61 0.20
Heart rate, bpm 0.12 0.74
Baseline systolic BP, mmHg 0.51 0.48
Baseline diastolic BP, mmHg 0.50 0.41
Smoking habits (yes/no) 0.41 0.53
Type II diabetes mellitus (yes/no) 0.48 0.62
Total cholesterol, mg/dl 0.12 0.72
HDL cholesterol, mg/dl 0.26 0.61
LDL cholesterol, mg/dl 0.19 0.66
Triglycerides, mg/dl 0.17 0.68
Glucose, mg/dl 0.12 0.72
Body mass index, kg/m2 0.61 0.83
Creatinine, mg/dl 0.71 0.36
BUN, mg/dl 0.93 0.82
Systolic BP change during follow-up, mmHg 9.8 0.05
Diastolic BP change during follow-up, mmHg 2.41 0.11
Use of ACE-inhibitors during follow-up (yes/no) 2.58 0.10
Use of ARBs during follow-up (yes/no) 0.98 0.65
Use of aldosterone inhibitors during follow-up (yes/no) 24.2 0.001
Use of double-blockade of RAAS (simultaneous use of an aldosterone  
inhibitor + an ACE-inhibitor or ARB) during follow-up (yes/no)
16.7 0.01
Use of diuretics during follow-up (yes/no) 0.42 0.45
Use of calcium channel blockers during follow-up (yes/no) 0.64 0.41
Use of beta adrenergic blockers during follow-up (yes/no) 0.41 0.54
Use of statins during follow-up (yes/no) 1.99 0.21
Use of oral hypoglycaemic drugs during follow-up (yes/no) 0.14 0.15
Brachial artery diameter at baseline, mm 0.23 0.81
Baseline FMD, % 0.66 0.78
Baseline NTG-MD, % 0.65 0.74
Abbreviations: see Tables 1 and 2.
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The initial aim of the present study was to investigate 
the role of the various classes of antihypertensive drugs 
on the improvement of endothelial function in a specific 
population of hypertensive postmenopausal women. The 
main result of the study, i.e. the importance of aldosterone 
inhibition, was not a pre-specified objective, but emerged 
from post-hoc data analysis. This is why our patients did 
not undergo evaluation of circulating blood concentra-
tions of aldosterone at baseline, nor evaluation of the 
aldosterone–renin ratio. Moreover, none of our patients 
had symptoms suggestive of hyperaldosteronism, and, in 
addition, the plasma potassium levels showed similar lev-
els in the two study groups at baseline, and none of our 
women had significant hypokalaemia (potassium levels 
below 3.5 mEq/L).
An important consideration is that aldosterone inhibitors 
have been reported as effective in treating resistant hyper-
tension, especially in obese patients and in patients with 
sleep apnoea syndrome.36 In our series, baseline BP are 
comparable between groups and, in addition, the number of 
drugs useful in achieving optimal BP values is statistically 
not different between groups. No patient in our cohort suf-
fered from sleep apnoea syndrome, and there were no 
Figure 1. Regression analysis between change in flow-mediated dilatation (FMD) and change in blood pressure (BP) values during 
follow-up (r = –0.12, p < 0.05).
significant differences, relative to all studied parameters 
(including the prevalence of obesity), between groups. 
The present study presents several strengths, including 
the prospective design, the homogeneous sample, and the 
strict follow-up of the participants. All of these factors sup-
port us to hypothesize, in postmenopausal hypertensive 
women, a significant influence of antihypertensive pharma-
cological treatment on the recovery of endothelial dysfunc-
tion. In addition, we highlight the importance of inhibiting 
aldosterone receptors in order to additionally improve 
endothelial function.
Although the present data are encouraging, it is oppor-
tune to specify that the routine clinical use of the non- 
invasive evaluation of endothelial function on an individual 
basis may be premature, because the test is still not com-
pletely standardized, and is costly and rather labour inten-
sive. Moreover, the value of the present study is to provide 
biological insight rather than practical implications. The 
encouraging results of the present study, for the significant 
impact on endothelial function, may be used for planning 
new randomized trials to assess whether the addition of an 
aldosterone inhibitors actually translates into a significant 
clinical impact in hypertensive populations. 
Rossi et al. 453
Table 5. Main demographic, anthropometric, clinical and brachial artery characteristics of the patients, divided according to 
whether or not taking aldosterone inhibitors
Parameter Group 1: patients taking  
aldosterone inhibitors (n = 49)
Group 2: patients NOT taking 
aldosterone inhibitors (n = 271)
Demographic, anthropometric, clinical variables and cardiovascular risk factors, at baseline
Age, years 57 ± 7 57 ± 8
Current smokers 22.4% (n = 11) 21.8% (n = 59)
Total cholesterol, mg/dl 205 ± 45 209 ± 42
HDL cholesterol, mg/dl 47 ± 12 51 ± 15
LDL cholesterol, mg/dl 113 ± 38 112 ± 38
Hypercholesterolaemia 32.6% (n = 16) 32.5% (n = 88)
Triglycerides, mg/dl 159 ± 89 162 ± 88
Glucose, mg/dl 100 ± 18 104 ± 25
Type 2 diabetes mellitus  8.1% (n = 4)  8.1% (n = 22)
BMI, kg/m2 26.7 ± 4.2 27.5 ± 4.5
Obesity* 
(BMI ≥ 30 kg/m2)
 6.1% (n = 3)  7.0% (n = 19)
Heart rate, bpm 81 ± 13 79 ± 13
Framingham Risk Score† 7.6 ± 6.3 7.7 ± 6.6
Blood pressure
Baseline (systolic / diastolic), mmHg 156 ± 16 / 93 ± 11 157 ± 15 / 94 ± 10
After 6 months (systolic / diastolic), mmHg 133 ± 14 / 82 ± 10a 134 ± 15 / 83 ± 10a
Liver function-related parameters, at baseline
Total bilirubin, mg/dl 0.78 ± 0.38 0.77 ± 0.39
AST, IU/L 25 ± 9 23 ± 9
ALT, IU/L 28 ± 15 28 ± 16
γ-GT, IU/L 36 ± 27 37 ± 30
Renal function-related parameters, at baseline
Creatinine, mg/dl 0.90 ± 0.35 0.99 ± 0.29
BUN, mg/dl 34 ± 9 30 ± 11
Uric acid, mg/dl 5.5 ± 1.2 5.5 ± 1.4
Renal function-related parameters, after six months of follow-up
Creatinine, mg/dl 1.02 ± 0.38 0.98 ± 0.31
BUN, mg/dl 39 ± 9 38 ± 10
Uric acid, mg/dl 5.9 ± 1.5 5.6 ± 1.3
Serum electrolytes,  at baseline
Sodium, mEq/L 141 ± 6 139 ± 5
Potassium, mEq/L 4.0 ± 0.5 4.1 ± 0.4
Serum electrolytes, after six months of follow-up
Sodium, mEq/L 140 ± 8 140 ± 6
Potassium, mEq/L 4.5 ± 0.8 4.3 ± 0.5
Antihypertensive medications
Dual blockade of RAAS (aldosterone receptor blocker 
+ ACE-inhibitor or ARB)
75.5% (n = 37) 0b
Use of ACE-inhibitor 55.1% (n = 27) 36.2% (n = 98)c
Use of ARB 20.4% (n = 10) 40.6% (n = 110)d
Medications, other than antihypertensive drugs
Statins 30.6% (n = 15) 29.9% (n = 81)
Oral hypoglycaemic drugs  8.1% (n = 4)  8.1% (n = 22)
Brachial artery characteristics, at baseline
BAD, mm 3.9 ± 0.5 3.9 ± 0.7
FMD, % 8.0 ± 1.3 8.3 ± 1.1
NTG-MD, % 18.9 ± 3.2 18.1 ± 2.8
Brachial artery characteristics, after six months of follow-up
BAD, mm 4.0 ± 0.8 3.9 ± 0.7
FMD, % 14.3 ± 1.7e 11.5 ± 1.4a
NTG-MD, % 18.5 ± 2.2 17.9 ± 2.6 
ap < 0.0001 intra-group (vs. baseline) comparison. bp < 0.0001 inter-group comparison. cp < 0.01 inter-group comparison. dp < 0.001 inter-group 
comparison. ep < 0.0001 intra-group (vs. baseline), and p < 0.01 inter-group (vs. group 2) comparisons. Abbreviations: see Table 1. *: according to the 
world health organization criteria, †: http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof.
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